论文部分内容阅读
目的探讨血清中LDH、α-HBDH水平在恶性肿瘤诊断及其进展中的临床价值。方法应用贝克曼AU5800系列全自动生化分析仪对245例恶性肿瘤、230例良性肿瘤的患者及236例同期健康体检者组成的健康对照组分别进行血清LDH、α-HBDH测定,将不同系统肿瘤的指标水平进行统计学分析比较。选取消化系统恶性肿瘤病例进行研究,研究初诊组、难治转移组和治疗缓解组血清LDH、α-HBDH水平差异。应用SPSS17.0对数据进行整理和统计学分析。结果恶性肿瘤组与良性肿瘤组及健康对照组比较,LDH、α-HBDH水平明显升高(P<0.05);良性肿瘤组与健康对照组比较差异无统计学意义。在各系统中,消化系统恶性肿瘤患者血清中的LDH、α-HBDH水平最高。其中难治转移组表达水平较初诊组与治疗缓解组均明显升高(P<0.05);治疗缓解组与初诊组比较,血清中LDH、HBDH水平明显降低(P<0.05)。结论血清LDH与α-HBDH水平在恶性肿瘤患者明显升高;对血清中LDH、α-HBDH活力的检测,可作为消化系统恶性肿瘤诊断及治疗中的参考指标。
Objective To investigate the clinical value of serum LDH and α-HBDH levels in the diagnosis and progression of malignant tumors. Methods Serum LDH and α-HBDH were measured by Beckman AU5800 series automatic biochemical analyzer in 245 patients with malignant tumors, 230 patients with benign tumors and 236 healthy controls at the same period. Serum levels of different system tumors Indicators for statistical analysis of the level of comparison. The patients with digestive system malignant tumor were selected to study the difference of serum LDH and α-HBDH levels in newly diagnosed group, refractory metastasis group and treatment-relieved group. Apply SPSS17.0 to organize and analyze the data. Results The levels of LDH and α-HBDH in malignant tumor group were significantly higher than those in benign tumor group and healthy control group (P <0.05). There was no significant difference between benign tumor group and healthy control group. In each system, the serum levels of LDH and α-HBDH in patients with digestive system malignancies were the highest. The expression of LDH and HBDH in the refractory metastasis group was significantly higher than that in the newly diagnosed group and the remission group (P <0.05). The LDH and HBDH levels in the remission group were significantly lower than those in the newly diagnosed group (P <0.05). Conclusions The levels of serum LDH and α-HBDH are significantly increased in patients with malignant tumors. The detection of serum LDH and α-HBDH activity can be used as a reference index in the diagnosis and treatment of digestive system malignancies.